Pharma BD Deal Intelligence

Bayer AG / Algeta ASA

2013 · Acquisition/Merger · $2.9B · Complete

Bayer agreed to acquire Algeta for ~NKr17.6B (~$2.9B) on a fully-diluted basis, gaining full control of partnered prostate-cancer therapy Xofigo and Algeta's pipeline of targeted alpha radiotherapies; Bayer initial Nov bid was $2.4B, raised to $2.9B in Dec.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Dec 19, 2013
• Closed Mar 04, 2014
• Deal value $2.9B
• Deal type Acquisition/Merger
• Therapeutic area Castration-resistant prostate cancer with bone metastases
• Indications Castration-resistant prostate cancer with bone metastases
• Key assets Xofigo (radium-223 dichloride)
• Mechanism Alpha-particle-emitting radiopharmaceutical (Ra-223 calcium mimetic)

← Browse all deals  ·  How we score deals